poster listing - isop 2017 -...
TRANSCRIPT
-
115 18 October 2017 | ACC, Liverpool, UK | www.isop2017liverpool.org
POSTER LISTING
Monday 16th October 2017
Poster No. Abstract / Paper Title / Presenter
Theme: Health data science including big data
1
Abstract 160Does a good institutional reporting culture extend to the reporting of yellow cardsTohfa Ahmad, West Midlands Centre For Adverse Drug Reaction Reporting, United Kingdom
2
Abstract 11Parents perception and practices regarding immunization: a cross sectional investigation Thamir Alshammari, University Of Hail, Saudi Arabia
3
Abstract 132Selective Serotonin Reuptake Inhibitors (SSRIs) and major congenital heart defects (CHDs): An analysis of FDA spontaneous adverse event report databases Sameh-Al-Zubedi, The University Of Jordan, Jordan
4
Abstract 148Does the use of vancomycin is efficient and safety in renal failure patients? Mehdi Bouhlel, National Center of Pharmacovigilance, Tunisia
5
Abstract 202The effect of concomitant antiepileptic drugs on plasma lamotrigine concentrationMehdi Bouhlel, National Center of Pharmacovigilance, Tunisia
6
Abstract 62Reducing prescribing errors associated with inpatient electronic prescribing systems: An investigation of pharmacist interventions to prevent prescribing errors Anthony Cox, University Of Birmingham, United Kingdom
192 posters have been successfully accepted for this years 17th ISoP Annual Meeting. Posters will be displayed in the exhibition hall
area with half of the posters being displayed on Monday and half of Tuesday. Official poster session times are:
Poster judging will take place during the conference and the three best posters will be awarded during the poster prize ceremony on
Wednesday, 18 October 13.00
Date Time
Monday 16th October 13:00 - 14:00
Tuesday 17th October 14:00 - 15:00
-
2 15 18 October 2017 | ACC, Liverpool, UK | www.isop2017liverpool.org
7
Abstract 119Proactive pharmacovigilance : description of nivolumabs safety informations identified through the clinical data warehouse of a French University Hospital Hlne Jantzem, Centre Rgional De Pharmacovigilance / Chru De Brest, France
8
Abstract 224Use of hospital data to estimate burden of adverse drug eventsMark Lillie, Cognizant, United Kingdom
9
Abstract 31Supporting pharmacovigilance by landscaping EU-funded real world dataKelly Plueschke, European Medicines Agency, United Kingdom
10
Abstract 27Multi-Level Modelling (MLM) in Specialist Cohort Event Monitoring (SCEM) studies Saad Shakir, Drug Safety Research Unit, United Kingdom
Theme: Miscellaneous
11
Abstract 87Safety of the hexavalent vaccine as used in general practice: Interim results from a prospective observational study Noemi Beatrix Bulik, Iuliu Hatieganu University Of Medicine And Pharmacy Cluj-Napoca, Romania
12
Abstract 83Bogota Declaration: The intention to promote both cooperation concerning safe use of medicines and pharmacovigilance development in Latin America Rosa Angela Caro-Rojas, Colombian Pharmacovigilance Association, Colombia
13
Abstract 241Drug-injury relief system for patient benefit in Taiwan: The 20 years of experience Wen Wen Chen, Taiwan Drug Relief Foundation, Taiwan
14
Abstract 30Deaths from medicines: A systematic analysis of UK Coroners reports to prevent future deaths Anthony Cox, University Of Birmingham, United Kingdom
15
Abstract 56Contraceptive and pregnancy testing requirements in clinical trials from French academic sponsors Sabrina Crepin, Chu De Limoges, France
16
Abstract 217Primary challenges to conducting post-marketing observational research in Sub-Saharan Africa: Preliminary results Laura Devore, DSRU, Switzerland
POSTER LISTING
-
315 18 October 2017 | ACC, Liverpool, UK | www.isop2017liverpool.org
POSTER LISTING
17
Abstract 267Disposal of unused and expired medicines by consumers Implications for ecopharmacovigilance Yvonne Yirenkyiwaa Esseku, Rapha Consult, Ghana
18
Abstract 9Olpadronate retrospective compilation of adverse events: Determination of Dose of Exposition (DOE) until the first adverse event occurrence Guadalupe Garca Darderes, Gador S.A., Argentina
19
Abstract 218Making safer medicines: Improving labeling and packaging to prevent medication errors Santiago Garnica, Vitalis, Colombia
20
Abstract 153Local success is global success Addressing the challenges of implementing product risk minimization globally Jeffrey Ho, Navitas, United Kingdom
21
Abstract 21Alternative facts: Why patient safety is under threat and what we can do about it Bruce Hugman, Uppsala Monitoring Centre, Thailand
22
Abstract 82Number Needed to Treat to Harm (NNTH) to assess the risk of cataracts associated with statins in observational studies Diogo Mendes, Aibili, Portugal
23
Abstract 116Overview of systematic reviews of therapeutic ranges: Establishing the threshold of increased drug toxicity James Moss, Bcuhb, United Kingdom
24
Abstract 112Assessment of cancer patients knowledge of the management of adverse reactions at the Mohammed V Rabat Military Instruction Hospital Naoual Nchinech, Mohamed V Military hospital, Morocco
25
Abstract 28Are NSAIDs really cheap medications? Marcelo Ponte, Pontificia Universidad Catolica Buenos Aires, Argentina
26
Abstract 12A way to classify the prescriptive cascades Marcelo Ponte, Pontificia Universidad Catolica Buenos Aires, Argentina
-
4 15 18 October 2017 | ACC, Liverpool, UK | www.isop2017liverpool.org
POSTER LISTING
27
Abstract 13Pevalence of prescriptive cascades Marcelo Ponte, Pontificia Universidad Catolica Buenos Aires, Argentina
28
Abstract 39Measuring the impact of product withdrawals and other major pharmacovigilance actions on public health burden in the EU: Methodological considerations Saad Shakir, Drug Safety Research Unit, United Kingdom
29
Abstract 44By selecting journals for monitoring by branches of medicine, MAHs can risk missing almost half of their ICSRs Katalin Timr-Horvth, Comfit Europe Ltd., Hungary
30
Abstract 45Big data of local medical literature monitoring Katalin Timr-Horvth, Comfit Europe Ltd., Hungary
31
Abstract 208Analysis and comparison of risk management tools Banu Unal, Bayer/Marmara University, Turkey
32
Abstract 109Latency period of crying following vaccination with MMR vaccine. What do spontaneous AEFI-reports show? Annet Van Boekel, Pharmacovigilance Center Lareb, Netherlands
33
Abstract 127Use of a medicine chart in promoting the safe use of Antiretrovirals amongst adults at Mbagathi Hospital in Nairobi, Kenya Catherine Wambura, Mbagathi Hospital, Kenya
Theme: Pharmacogenomics and pharmacovigilance
34
Abstract 97What do patients know about Yellow Cards?Alana Adams, YCC Wales, United Kingdom
35
Abstract 107Impact of serious adverse drug reactions on the quality of life of patients on HAART, in UMTH Maiduguri, North-East Nigeria Peter Bassi, University, Nigeria
36
Abstract 185Adverse events following Immunization: injection site abcesses Mehdi Bouhlel, National Center of Pharmacovigilance, Tunisia
-
515 18 October 2017 | ACC, Liverpool, UK | www.isop2017liverpool.org
POSTER LISTING
37
Abstract 264Clinical decision support tool for genetic HLA testing to predict, pre-empt and diagnose adverse drug reactions Gurpreet Ghattaoraya, University Of Liverpool, United Kingdom
38
Abstract 213A comparison of classification procedures and custom event terms in differentiating drug scheduling classes Eric Hung, Pfizer Inc, United States
40
Abstract 199Activity report of the pharmacovigilance unit of the Mohammed V Military Instruction Hospital Rabat Morocco May 2016 - March 2017Naoual Nchinech, Mohamed V Military hospital, Morocco
41
Abstract 66How do adverse drug reactions influence the patients daily life? Qualitative analysis on spontaneous reports by patients Len Rolfes, Netherlands Pharmacovigilance Centre Lareb, Netherlands
42
Abstract 159Non-medical prescriber experiences of training and competence to report adverse drug reactions Andrew Thompson, University Of Liverpool, United Kingdom
43
Abstract 252The role of pharmacovigilance in the development of pharmacogenetics treatments Banu Unal, Bayer/Marmara University, Turkey
Theme: Pharmacovigilance in specific settings (oncology, biologics, biosimilars, cell therapies, herbals
44
Abstract 104Oncogeriatric pharmacovigilance: a review of observational data Malak Abou Taam, Facult De Mdecine, Universit De Reims Champagne, France
45
Abstract 103Frail and elderly patient in oncology: Increased drug toxicities?Malak Abou Taam, Facult De Mdecine, Universit De Reims Champagne, France
46
Abstract 32Concurrent use of prescription medicines and herbal medicinal products among older adults: A systematic review Taofikat Agbabiaka, University Of Hertfordshire, United Kingdom
47
Abstract 203Adverse drug reactions reporting versus medication errors reporting in public hospitals using patient safety network system Fatima Albreiki, Abu Dhabi Health Services, United Arab Emirates
-
6 15 18 October 2017 | ACC, Liverpool, UK | www.isop2017liverpool.org
POSTER LISTING
48
Abstract 261Evaluation of the antimicrobial effect of expired oral antibioticsKawthar Alghasham, Pharmacist, Saudi Arabia
49
Abstract 244Ongoing elevated risk of developing tuberculosis in rheumatological conditions where Anti-TNF-alpha agents were used: Results of 2-year retrospective cohort studyVolkan Aydin, Marmara University School Of Medicine Department Of Pharmacology, Turkey
50
Abstract 242Reintroduction of reference infliximab product in patients showing inefficacy to its biosimilarSamy Babai, Pharmacovigilance, France
51
Abstract 37Dolutegravir withdrawal and adverse drug reactions: A retrospective study in Midi-PyrnesHaleh Bagheri, Service De Pharmacologie Mdicale Et Clinique, Centre De Pharmacovigilance, France
52
Abstract 35Towards web-based, purchase-event intensive monitoring for pharmacovigilance of Natural Health Products (NHPs): Lessons from development work Jo Barnes, University Of Auckland, New Zealand
53
Abstract 187Hypersensitivity reaction associated with intravenous administration of folinic acid in patient with gastric cancer Mehdi Bouhlel, National Center of Pharmacovigilance, Tunisia
54
Abstract 182Adverse drug reactions reports for trastuzumab: An analysis of Brazilian pharmacovigilance database and VigiBase/WHO and EudraVigilance/EMAFlvia Campos Barcelos, National Cancer Institute (INCA), Brazil
55
Abstract 198Unexpectedly high fatality rate in globally collected spontaneous reports of Progressive Multifocal Leukoencephalopathy with AlemtuzumabOla Caster, Uppsala Monitoring Centre, Sweden
56
Abstract 63The RE-AIM Framework and REVLIMID REMS program: A methodology for REMS assessmentMay Chan-Liston, Celgene Corporation, United States
57
Abstract 50Three cases of seizure with nivolumab: A new class of adverse effects for the anti-PD-1 immunotherapy?Vassili Chawadronow, Chu De Caen, France
-
715 18 October 2017 | ACC, Liverpool, UK | www.isop2017liverpool.org
POSTER LISTING
58
Abstract 142Data management in pharmacovigilance: Challenges and complexities Mugdha Chopra, Apcer Life Sciences, India
59
Abstract 7Application of the Bleeding Academic Research Consortium (BARC) Definition for bleeding outcomes within a post authorization safety studyMiranda Davies, Drug Safety Research Unit, United Kingdom
60
Abstract 90Natalizumab and rapidly evolving central nervous system lymphoma in VigiBaseBirgitta Grundmark, WHO-UMC, Sweden
61
Abstract 72Enhanced safety surveillance for seasonal influenza vaccines: A year-to-year comparison of suspected adverse drug reactions Lorna Hazell, DSRU Education & Research Ltd., United Kingdom
62
Abstract 250Alopecia during a spa: what link with INFLIXIMAB?Khadija Lechheb, Hopital Militaire Mohammed V, Morocco
63
Abstract 253Peripheral neuropathy and nails blue coloration under Folfiri-Bevacizumab khadija lechheb, Hopital Militaire Mohammed V, Morocco
64
Abstract 19Adverse drug reactions as a cause of admission to intensive care unit : A 4-months prospective cohort studyFrancoise Livio, Division Of Clinical Pharmacology, Switzerland
65
Abstract 58Suspected adverse reactions to herbal dietary supplements for weight loss collected by the Italian surveillance system on natural productsFrancesca Menniti-Ippolito, Italian National Institute Of Health, Italy
66
Abstract 57Suspected adverse reactions to alpha lipoic acid-containing food supplements: Analysis of the Italian Surveillance System of Natural Health ProductsFrancesca Menniti-Ippolito, Italian National Institute Of Health, Italy
67
Abstract 67Suspected adverse reactions to cannabis galenic preparations for medical use in Italy Francesca Menniti-Ippolito, Italian National Institute Of Health, Italy
-
8 15 18 October 2017 | ACC, Liverpool, UK | www.isop2017liverpool.org
POSTER LISTING
68
Abstract 145Guillain-Barr Syndrome associated with vaccines in children: A case-control studyFrancesca Menniti-Ippolito, Italian National Institute Of Health, Italy
69
Abstract 157Intussusception cases in an Italian pediatric populationFrancesca Menniti-Ippolito, Italian National Institute Of Health, Italy
70
Abstract 113Pharmacovigilance requirements for clinical trials in emerging markets in AsiaSanjeev Miglani, Apcer Life Sciences, India
71
Abstract 76Comparative safety of targeted therapies for mCRC treatment between young and elderly patients: A study using VigiBaseGhada Miremont Salame, Centre de Pharmacovigilance de Bordeaux, France
72
Abstract 85Safety of BRAF and MEK inhibitors for treatment of metastatic melanoma: Analysis of the WHO database of adverse eventsGhada Miremont Salame, Centre de Pharmacovigilance de Bordeaux, France
73
Abstract 101Utilisation and safety of Deferasirox (Exjade) in older adults: Results from an observational cohort study in England Saad Shakir, Drug Safety Research Unit, United Kingdom
74
Abstract 230Does the corossol fruit really treat cancer?Souad Skalli, Faculty of Science. Mohammed V University, Morocco
75
Abstract 233Launch of pilot reporting scheme for harms associated with new psychoactive substancesAlexander Smith, MHRA, United Kingdom
76
Abstract 144Epidemiological and clinical profile of adverse effects of antineoplastic agents, Pharmacovigilance in oncology, Morocco, 2012 2016Ismail Talibi, Ecole Nationale de Sant Publique de Rabat, Centre Anti Poison Et De Pharmacovigilance Du Maroc,
Morocco
77
Abstract 135Adverse drug reactions in oncology: Intensive monitoring program on biotechnological and target therapies in oncologic patients ALEXANDROS observational studyMarco Tuccori, University Hospital, Italy
-
915 18 October 2017 | ACC, Liverpool, UK | www.isop2017liverpool.org
POSTER LISTING
78
Abstract 130Infections and serious infections as risks of rituximab in rheumatoid arthritis. Results from an updated meta-analysis of randomised clinical trialsLuis Velez, University of Basel, Switzerland
79
Abstract 129Post-marketing safety of deferasirox in combo vs monotherapy, a comparative assessmentLuis Velez, University of Basel, Switzerland
80
Abstract 155Evaluation of compliance to the timing of childhood vaccinations following introduction of the Meningococcal B vaccine in the UK Jenny Wong, Medicines And Healthcare Products Regulatory Agency, United Kingdom
Theme: Social media, electronic media and pharmacovigilance
81
Abstract 117The Aspidium Project: A versatile app concept to support risk minimisation at patient levelJean-Christophe Delumeau, ISoP, Singapore
82
Abstract 24Awareness survey on pharmacovigilance: Design of an online program for Argentinean health care professionals Guadalupe Garca Darderes, Gador S.A., Argentina
83
Abstract 236Evaluation of the first EU-wide social media ADR awareness week: 7-11 November 2016 Mitul Jadeja, MHRA, United Kingdom
84
Abstract 196Baclofene safety and its use in social media: A preliminary study Agnes Lillo Le Louet, Fdration De Pharmacovigilance Ile De France, France
85
Abstract 262Estimating the pertinent information present in social media, not just what an algorithm detects Simon Maskell, University of Liverpool, United Kingdom
86
Abstract 263Looking longitudinally in Twitter: reading more than 140 characters Simon Maskell, University of Liverpool, United Kingdom
87
Abstract 196Safety profile of fractional dosing of yellow fever vaccine, experience from community based vaccine pharmacovigilance in Kinshasa Didier Nzolo Bomene, Unit Of Clinical Pharmacology and Pharmacovigilance, The Democratic Republic of Congo
-
10 15 18 October 2017 | ACC, Liverpool, UK | www.isop2017liverpool.org
POSTER LISTING
88
Abstract 126Risk management by using ADRs reports via social media Yaowares Oppamayun, Health Product Vigilance Center, Thailand
89
Abstract 133A clinician network for sharing patients experiences in pharmacovigilance: The PHARMACOWIKILANCE project Marco Tuccori, University Hospital, Italy
90
Abstract 189Abstract Impact of internet and social media use in pharmacovigilance Banu Unal, Bayer/Marmara University, Turkey
Theme: Training in pharmacovigilance
91
Abstract 128Off-label drug use and Adverse Drug Events (ADEs) in paediatric patients: An analysis of the Jordanian National Pharmacovigilance Database Sameh Al-Zubiedi, The University of Jordan, Jordan
92
Abstract 146Influencing adverse drug reaction reporting in primary care Christopher Anton, Yellow Card Centre West Midlands, United Kingdom
93
Abstract 34Turkish physicians pharmacovigilance and adverse drug reaction reporting knowledge, attitude, and practicesMberra Devrim Gner, Tobb Economy & Technology University Medical School, Turkey
94
Abstract 151Funding for neglected tropical diseases to boost pharmacovigilance staff capacity in low and middle income countriesJerry Liwono Yana, National Pharmacovigilance Centre, The Democratic Republic of Congo
95
Abstract 265Strengthening Collaborations for Operating Pharmacovigilance in Europe (SCOPE) joint action: Supporting medicines regulators in EU to improve public health Louise Loughlin, MHRA (SCOPE Joint Action), United Kingdom
96
Abstract 184Brazilian regulation in drug surveillance Ftima Roque, Institute of Biomedicine of University of Aveiro, Portugal
-
1115 18 October 2017 | ACC, Liverpool, UK | www.isop2017liverpool.org
POSTER LISTING
Tuesday 17th October 2017
Poster No Abstract / Paper Title / Presenter
Theme: Clinical approaches in risk management
97
Abstract 143Effectiveness of clinical pharmacist review of direct oral anticoagulants prescriptions and scope of identified errors Ophir Lavon, Carmel Medical Center, Israel
98
Abstract 205Implementation of an integrative risk management plan for the safe practice of anticoagulants Ophir Lavon, Carmel Medical Center, Israel
99
Abstract 64Antibiotics use - Attitudes and practices of first year nursing students Ftima Roque, Institute of Biomedicine of University of Aveiro, Portugal
100
Abstract 73Adherence to therapeutic in outpatients: Literature review Ftima Roque, Institute of Biomedicine of University of Aveiro, Portugal
101
Abstract 186Safety and efficacy of different hyperkalaemia pharmacotherapies and their use in distinct clinical conditions Ftima Roque, Institute of Biomedicine of University of Aveiro, Portugal
102
Abstract 70Potentially inappropriate medicines in elderly patients - studies using the European screening tool, EU(7)-PIM list Ftima Roque, Institute of Biomedicine of University of Aveiro, Portugal
103
Abstract 222Contributing factors to the appearance of adverses events related to injectable Iron complexes Amina Tebaa, Centre Anti Poison Et De Pharmacovigilance, Morocco
Theme: Drug-induced organ specific injury (liver, skin, kidneys and other organs)
104
Abstract 106Cerebral pseudoatrophy, dementia and valproate Malak Abou Taam, Facult De Mdecine, Universit De Reims Champagne, France
105
Abstract 162idiosyncratic drug-induced liver injury: A 20-year update of the cases enrolled by the Spanish Dili registry Raul J. Andrade, Universidad De Malaga, Spain
-
12 15 18 October 2017 | ACC, Liverpool, UK | www.isop2017liverpool.org
POSTER LISTING
106
Abstract 163Analysing drug-host interplay in clinical presentation of drug-induced liver injury using data mining techniques Raul J. Andrade, Universidad De Malaga, Spain
107
Abstract 228Relevance of safety data in the withdrawal decision of hepatotoxic drugs Samy Babai, Pharmacovigilance, France
108
Abstract 234Generation of a novel, personalised in vitro model to assess the impact of mitochondrial DNA variation upon susceptibility to hepatotoxicity Amy Ball, University of Liverpool, United Kingdom
109
Abstract 174Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome induced by imatinib Mehdi Bouhlel, National Center of Pharmacovigilance, Tunisia
110
Abstract 214Fatal toxicity with a single IM dose of methotrexate in a patient treated for an ectopic pregnancy Mehdi Bouhlel, National Center of Pharmacovigilance, Tunisia
111
Abstract 231Fever, eosinophilia, and abnormal liver function are early signs suggestive of DRESS: A comparative study between DRESS and MPE Chia-Yu Chu, National Taiwan University Hospital, Taiwan
112
Abstract 237Mechanisms of chemotherapy-induced diarrhoea Stephanie French, University Of Liverpool, United Kingdom
113
Abstract 108Early onset vemurafenib-cobimetinib induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome: a case series Laurence Lagarce, Service de Pharmacologie Toxicologie et Pharmacovigilance CHU Angers Angers, France
114
Abstract 18Direct oral anticoagulants: Are they safer than vitamin K antagonists?Francoise Livio, Division Of Clinical Pharmacology, Switzerland
115
Abstract 223Abnormalities in liver or kidney function tests among patients treated for multi-drug resistant Tuberculosis in KinshasaYves Lula, Clinical Pharmacology And Pharmacovigilance Unit, The Democratic Republic of Congo
-
1315 18 October 2017 | ACC, Liverpool, UK | www.isop2017liverpool.org
POSTER LISTING
116
Abstract 5Statins and diabetes: Are all statins at risk?Jean-Louis Montastruc, Facult De Mdecine De Toulouse, France
117
Abstract 247Profile of Allopurinol toxidermia: A series of 24 casesYoussef Moutaouakkil, Faculty Of Medicine And Pharmacy, University Mohammed V, Morocco
118
Abstract 249Toxic epidermal necrolysis due to betalactamins: 2 case reportsAmal Mrani Alaoui, Ibn Sina University Hospital, Morocco
119
Abstract 266Checkpoint Inhibitor induced thyroid immune related adverse events: Two distinct clinical patternsAnna Olsson-Brown, University Of Liverpool, United Kingdom
120
Abstract 110Hepatotoxicity associated with anti-tuberculosis drugs. A case series from hospitalized patients in Lima, PerTeodoro Oscanoa, Centro Investigacin Seguridad Medicamentos. FMH - IdI. Universidad San Martin De Porres,
Peru
121
Abstract 78Angiotensin II receptor blockers and psoriasis: An analysis of the French pharmacovigilance databaseThierry Trenque, Pharmacovigilance Department, France
122
Abstract 235Evaluation of the risk of Denosumab-associated HypocalcaemiaThierry Trenque, Pharmacovigilance Department, France
Theme: Miscellaneous
123
Abstract 105Safety and availability of codeine in FranceMalak Abou Taam, Ea 3797, Facult De Mdecine, Universit De Reims Champagne Ardenne, France
124
Abstract 138Comparative risk of cause-specific mortality in older patients prescribed codeine or tramadol for non-malignant pain: Retrospective cohort studyCraig Allen, Medicines And Healthcare Products Regulatory Agency (MHRA), United Kingdom
125
Abstract 115Disease-Modifying Antirheumatic Drugs (DMARDs) utilisation in autoimmune rheumatic diseasesLaura Alexandra Anghel, University Of Medicine And Pharmacy Iuliu Hatieganu- Faculty Of Pharmacy Ecoimma,
Romania
-
14 15 18 October 2017 | ACC, Liverpool, UK | www.isop2017liverpool.org
POSTER LISTING
126
Abstract 225Regulation of e-cigarettes: Ensuring patient safety and product qualityHelena Bird, Medicines And Healthcare Products Regulatory Agency, United Kingdom
127
Abstract 164Near real-time monitoring of the anticipated benefit-risk of vaccines using an interactive dashboard: A proposition from ADVANCEKaatje Bollaerts, P95, Belgium
128
Abstract 134Biological substantiation of antipsychotic-associated pneumonia: Literature review and computational analysesJanet Sultana, University Of Messina, Italy
Theme: Signal detection and evaluation
129
Abstract 141Bisphosphonate-induced carpal tunnel syndrome. A disproportionality analysis in VigiBaseAlfonso Carvajal, Universidad de Valladolid, Spain
130
Abstract 68Tailoring signal detection methodologies in a global database to focus on safety concerns reported by patientsRebecca Chandler, Uppsala Monitoring Centre - Who Collaborating Centre For International Drug Monitoring,
Sweden
131
Abstract 52Developing a signal detection and prioritisation triage logic for the Korea adverse event reporting system-foreign database: Results of pilot studyYunhui Do, Korea Institute Of Drug Safety & Risk Management, South Korea
132
Abstract 42HOPIPRAC, PRAC signals validation sentinel system, from a hospital data warehouseLayal El Aridi, Centre Rgional De Pharmacovigilance / Chru De Brest, France
133
Abstract 239A description of new safety signals detected and assessed by PRAC at EU level in 2014-2016Andreea Farcas, University Of Medicine And Pharmacy Cluj-Napoca, Romania
134
Abstract 95Do they all agree? Comparing expert signal assessmentBirgitta Grundmark, WHO-UMC, Sweden
-
1515 18 October 2017 | ACC, Liverpool, UK | www.isop2017liverpool.org
POSTER LISTING
135
Abstract 61An example of robust pharmacovigilance practice: A safety signal of acute kidney injury with combination therapy of piperacillin/tazobactam and vancomycinSilke Harmeyer, Pfizer Inc, United Kingdom
136
Abstract 210Evaluation of a predictive model for suspected drug-drug interactions in routine signal detectionSara Hult, Uppsala Monitoring Centre, Sweden
137
Abstract 207Interaction between rosuvastatin and ticagrelor resulting in rhabdomyolysisSara Hult, Uppsala Monitoring Centre, Sweden
138
Abstract 125Spontaneous reporting characteristics of HIV Antiretrovirals in VigiBase: Disproportionate analysis between Sub-Saharan Africa and the Rest of the WorldAndrea Kuemmerle, Swiss Tropical And Public Health Institute, Switzerland
139
Abstract 4Challenges of identifying safety signals in clinical trials Milena Miljkovic, PrimeVigilance, Serbia
140
Abstract 6Impact of pharmacovigilance and evaluation activities - A regulatory perspectiveRania Mouchantaf, Health Canada, Canada
141
Abstract 161Safety of meningococcal group B vaccine: Experience from the UKSuzie Seabroke, Medicines & Healthcare Products Regulatory Agency, United Kingdom
142
Abstract 152Robustness of the CPA-PRR method in Pharmacovigilance detectionlodie Sole, French Medicines And Health Products Agency, France
143
Abstract 171Comparison of the performances of data-mining methods for signals detection on two spontaneous reporting databaseslodie Sole, French Medicines And Health Products Agency, France
144
Abstract 139An analysis of spontaneous reports on adverse drug reactions in child and adolescent psychiatry in GermanyThomas Stammschulte, Drug Commission Of The German Medical Association, Germany
-
16 15 18 October 2017 | ACC, Liverpool, UK | www.isop2017liverpool.org
POSTER LISTING
145
Abstract 147Muscular adverse drug reactions associated with proton pump inhibitors: A disproportionality analysis using the Italian National Network of Pharmacovigilance databaseMarco Tuccori, University Hospital, Italy
146
Abstract 29Characteristics of adverse events following influenza vaccination: Comparison between spontaneous reports and reports from an intensive monitoring programmeLeontine Van Balveren, Lareb, Netherlands
147
Abstract 22A change point analysis to study the reporting pattern of ADRs after drug substitutionFlorence Van Hunsel, Netherlands Pharmacovigilance Centre Lareb, Netherlands
148
Abstract 20An MCEM-MTL framework for drug safety signal filtering and detection in spontaneous reporting systemsCao Xiao, IBM T.J. Watson Research Center, United States
Theme: Spontaneous ADR reporting
149
Abstract 257The Chester experience - The impact of an intervention to improve adverse drug reactions reporting in a district general hospitalAmmar Abbas, Countess Of Chester Hospital NHS Foundation Trust, United Kingdom
150
Abstract 251Attitudes of non-medical nurse prescribers towards reporting adverse drug reactions via the yellow card scheme An exploratory studyAmmar Abbas, Countess Of Chester Hospital NHS Foundation Trust, United Kingdom
151
Abstract 38Adverse drug reactions related to direct oral anticoagulant: Patients internet narratives versus pharmacovigilance databaseHaleh Bagheri, Service De Pharmacologie Mdicale Et Clinique, Centre De Pharmacovigilance, France
152
Abstract 71Fetal impregnation with olanzapine: A case report Marie-Nolle Beyens, Pharmacovigilance, CHU de Saint-Etienne, France
153
Abstract 154Rabies vaccine-induced Adverse Drug Reactions (ADRs): What kind of serious ADRs?Marie-Nolle Beyens, Pharmacovigilance, CHU de Saint-Etienne, France
154
Abstract 197Evolution of the Western Cape Antiretroviral Pharmacovigilance Programme in South AfricaKaren Cohen, Division Of Clinical Pharmacology, Department Of Medicine, South Africa
-
1715 18 October 2017 | ACC, Liverpool, UK | www.isop2017liverpool.org
POSTER LISTING
155
Abstract 140Spontaneous reporting of adverse drug reactions associated with newer long-acting injectable antipsychotics in ItalyPaola Maria Cutroneo, Regional Pharmacovigilance Centre, Italy
156
Abstract 167Safety profile of direct-acting antivirals for Hepatitis C: An analysis of Italian spontaneous reporting system databasePaola Maria Cutroneo, Regional Pharmacovigilance Centre, Italy
157
Abstract 40Adverse drug reactions of anticoagulants in Norway in a two year period (2013-2015)Anne Katrine Eek, Relis, Oslo University Hosptal, Norway
158
Abstract 53Applying DoTS adverse drug reactions classification to reports from hospital spontaneous stimulated reportingAndreea Farcas, University Of Medicine And Pharmacy Cluj-Napoca, Romania
159
Abstract 554 years medication error reporting by German pharmacists: A disproportionality analysisMatthias Ganso, Drug Commission Of German Pharmacists (AMK), Germany
160
Abstract 204ADRs and medication errors surveillance after the implementation of an electronic report system Lourdes Garza-Ocanas, Universidad Autonma De Nuevo Len, Mexico
161
Abstract 122Opinion of Costa Rican pharmacists regarding some aspects of the Spontaneous Adverse Drug Reactions reporting 2017Victoria Hall, University of Costa Rica, Costa Rica
162
Abstract 229Survey on physicians knowledge, attitude and practice towards Adverse Drug Reaction (ADR) reporting in the Middle EastAhmed Hegazy, Merck, United Arab Emirates
163
Abstract 121Patient ADR reporting through stakeholders lens: Experiences in different EU countriesPedro Inacio, University Of Helsinki, Finland
164
Abstract 158Recording and assessing medication errors within a spontaneous reporting system: First resultsUrsula Kberle, Drug Commission Of The German Medical Association, Germany
-
18 15 18 October 2017 | ACC, Liverpool, UK | www.isop2017liverpool.org
POSTER LISTING
165
Abstract 124Contribution of Adverse Events Reporting of HIV Antiretrovirals to VigiBase: Comparison between Sub-Saharan Africa and the rest of the WorldAndrea Kuemmerle, Swiss Tropical And Public Health Institute, Switzerland
166
Abstract 248Cardiac toxicity after long-term treatment with chloroquine in a lupus patient Khadija Lechheb, Hopital Militaire Mohammed V, Morocco
167
Abstract 201Pharmacovigilance and patients: How to improve reports quality? Agnes Lillo Le Louet, Fdration De Pharmacovigilance Ile De France, France
168
Abstract 114A description and comparison of the adverse drug reaction profiles in people living with HIV administered antitubercular and/or antiretroviral medicationsJosiah Tatenda Masuka, WHO, Belgium
169
Abstract 92An unexpected digoxin overdose probably caused by a drug-drug-interaction after amiodarone withdrawal and apixaban initiation: A case reportChristophe Maucorps, Pharmacovigilance CHU Caen Basse-Normandie France, France
170
Abstract 91A further case report of hepatotoxicity induced by carbimazole with a positive rechallengeChristophe Maucorps, Pharmacovigilance CHU Caen Basse-Normandie France, France
171
Abstract 93Two cases of optic neuritis under golimumab therapy (anti-TNFa) for ankylosing spondylitis reveling central demyelinating disordersChristophe Maucorps, Pharmacovigilance CHU Caen Basse-Normandie France, France
172
Abstract 77Serious drug adverse reactions: A retrospective and descriptive study from the French regions of Bordeaux, Limoges, and PoitiersGhada Miremont Salame, Centre de Pharmacovigilance de Bordeaux, France
173
Abstract 16Knowledge and attitude of health care professionals toward adverse drug reactions reporting at King Saud Medical CityKhaja Moinuddin, King Saud Medical City, Saudi Arabia
174
Abstract 8Drugs, adverse drug reactions and pharmacovigilance in the Adventures of TintinJean-Louis Montastruc, Facult De Mdecine De Toulouse, France
-
1915 18 October 2017 | ACC, Liverpool, UK | www.isop2017liverpool.org
POSTER LISTING
175
Abstract 246Hemorrhagic stroke after thrombolysisAmal Mrani Alaoui, Ibn Sina University Hospital, Morocco
176
Abstract 221Hospital admission due to dysglycaemia among children in England and WalesAbdallah Naser, UCL School Of Pharmacy, United Kingdom
177
Abstract 111State of play on the reporting of adverse reactions of direct oral anticoagulants by doctors in Rabat (Morocco) in 2016Naoual Nchinech, Mohamed V Military hospital, Morocco
178
Abstract 168Challenges and resolutions in integrating electronic adverse drug reaction (ADR) reporting into UK clinical systems: A case studyRebecca Owen, MHRA, United Kingdom
179
Abstract 226Examination of the trends in medication error reporting post legislation changes in the United KingdomGowthamei Ragunathan, Medicines and Healthcare products Regulatory Agency, United Kingdom
180
Abstract 69Adverse drug reactions notifications by patientsFtima Roque, Institute of Biomedicine of University of Aveiro, Portugal
181
Abstract 65Rapid onset of very high INR values when roxithromycin prescribed with warfarin challenges the accepted mechanismMichael Tatley, New Zealand Pharmacovigilance Centre, University Of Otago, Dunedin, New Zealand
182
Abstract 219Methadone side effects and intoxication Amina Tebaa, Centre Anti Poison Et De Pharmacovigilance, Morocco
183
Abstract 51Eculizumab therapy and fatal seizures: About four cases Thierry Trenque, Pharmacovigilance Department, France
184
Abstract 23The contribution of direct patient reports to drug safety signals in the Netherlands from 2010-2015 Florence Van Hunsel, Netherlands Pharmacovigilance Centre Lareb, Netherlands
-
20 15 18 October 2017 | ACC, Liverpool, UK | www.isop2017liverpool.org
POSTER LISTING
185
Abstract 81The occurrence of ADRs of ADHD medication in the adult population: Collaboration with patient organisation contributing to medicine safety Gerda Weits, Netherlands Pharmacovigilance Centre Lareb, Netherlands
Theme: Womens health
186
Abstract 80Self-medication during the third trimester of pregnancy: A retrospective study Laurence Lagarce, Service de Pharmacologie Toxicologie et Pharmacovigilance CHU Angers, France
187
Abstract 118Breastfeeding women taking medications: About the need to collect data Gaboriau Louise, Regional Pharmacovigilance Center, France
188
Abstract 215Adverse events following immunization of pregnant women with Yellow Fever Vaccine in KinshasaDidier Nzolo Bomene, Unit Of Clinical Pharmacology and Pharmacovigilance, The Democratic Republic Of Congo
189
Abstract 256Medication errors in real clinical practice- Observational study among women undergoing assisted reproduction therapy Svetoslav Stoev, Medical University Sofia, Bulgaria
190
Abstract 96Intensive monitoring program of Teratogen and non-teratogen risk of drugs during pregnancy: The STORK projectMarco Tuccori, University Hospital, Italy
Theme: Health data science including big data
191
Abstract 43Patient Registries InitiativeKelly Plueschke, European Medicines Agency, United Kingdom
Theme: Pharmacogenomics and pharmacovigilance
192
Abstract 79Impact of weekly visits by Pharmacovigilance center pharmacist on questions about adverse drug reactions asked by intensive care unit practitionersLaurence Lagarce, Service de Pharmacologie Toxicologie et Pharmacovigilance CHU Angers, France